You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDimethylglycine
Accession NumberDB02083  (EXPT01225)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
CategoriesNot Available
CAS number1118-68-9
WeightAverage: 103.1198
Monoisotopic: 103.063328537
Chemical FormulaC4H9NO2
InChI KeyFFDGPVCHZBVARC-UHFFFAOYSA-N
InChI
InChI=1S/C4H9NO2/c1-5(2)3-4(6)7/h3H2,1-2H3,(H,6,7)
IUPAC Name
2-(dimethylamino)acetic acid
SMILES
CN(C)CC(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acids
Alternative Parents
Substituents
  • Alpha-amino acid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Betaine MetabolismMetabolicSMP00123
Glycine N-methyltransferase DeficiencyDiseaseSMP00222
Methionine MetabolismMetabolicSMP00033
S-Adenosylhomocysteine (SAH) Hydrolase DeficiencyDiseaseSMP00214
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)DiseaseSMP00340
Homocystinuria-megaloblastic anemia due to defect in cobalamin metabolism, cblG complementation typeDiseaseSMP00570
HypermethioninemiaDiseaseSMP00341
Cystathionine Beta-Synthase DeficiencyDiseaseSMP00177
Methionine Adenosyltransferase DeficiencyDiseaseSMP00221
Non Ketotic HyperglycinemiaDiseaseSMP00223
Glycine and Serine MetabolismMetabolicSMP00004
Dimethylglycine Dehydrogenase DeficiencyDiseaseSMP00242
SarcosinemiaDiseaseSMP00244
Hyperglycinemia, non-ketoticDiseaseSMP00485
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)DiseaseSMP00179
Dimethylglycine Dehydrogenase DeficiencyDiseaseSMP00484
3-Phosphoglycerate dehydrogenase deficiencyDiseaseSMP00721
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9652
Blood Brain Barrier+0.9325
Caco-2 permeable+0.6471
P-glycoprotein substrateNon-substrate0.7086
P-glycoprotein inhibitor INon-inhibitor0.9753
P-glycoprotein inhibitor IINon-inhibitor0.9693
Renal organic cation transporterNon-inhibitor0.9009
CYP450 2C9 substrateNon-substrate0.8119
CYP450 2D6 substrateNon-substrate0.8624
CYP450 3A4 substrateNon-substrate0.6141
CYP450 1A2 substrateNon-inhibitor0.8959
CYP450 2C9 substrateNon-inhibitor0.9751
CYP450 2D6 substrateNon-inhibitor0.9411
CYP450 2C19 substrateNon-inhibitor0.9739
CYP450 3A4 substrateNon-inhibitor0.9808
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9919
Ames testNon AMES toxic0.9363
CarcinogenicityCarcinogens 0.5934
BiodegradationReady biodegradable0.6461
Rat acute toxicity2.1692 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9489
hERG inhibition (predictor II)Non-inhibitor0.9504
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point185.5 °CPhysProp
boiling point63.9 °CPhysProp
logP-2.91TSAI,RS ET AL. (1991)
pKa2.04TSAI,RS ET AL. (1991)
Predicted Properties
PropertyValueSource
Water Solubility939.0 mg/mLALOGPS
logP-1.7ALOGPS
logP-3.1ChemAxon
logS0.96ALOGPS
pKa (Strongest Acidic)1.88ChemAxon
pKa (Strongest Basic)9.69ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity26.07 m3·mol-1ChemAxon
Polarizability10.47 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraGC-MSMS/MSLC-MS1D NMR2D NMR
References
Synthesis Reference

Roger V. Kendall, John W. Lawson, “Dimethylglycine enhancement of antibody production.” U.S. Patent US5118618, issued December, 1982.

US5118618
General ReferenceNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

1. Monomeric sarcosine oxidase

Kind: protein

Organism: Bacillus sp. (strain B-0618)

Pharmacological action: unknown

Components

Name UniProt ID Details
Monomeric sarcosine oxidase P40859 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:17